Provided by Tiger Trade Technology Pte. Ltd.

MediciNova

1.54
-0.0700-4.35%
Post-market: 1.550.0100+0.65%19:30 EDT
Volume:109.38K
Turnover:169.83K
Market Cap:75.69M
PE:-7.04
High:1.61
Open:1.60
Low:1.53
Close:1.61
52wk High:3.90
52wk Low:1.17
Shares:49.15M
Float Shares:43.50M
Volume Ratio:0.57
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2188
EPS(LYR):-0.2445
ROE:-25.56%
ROA:-16.41%
PB:2.03
PE(LYR):-6.30

Loading ...

MediciNova Management to Join Maxim Growth Summit, Offers Investor Meetings

Reuters
·
Oct 06

3D Investment Partners Cuts Stake in Medicinova to 9.88% from 11.22%, Filing Shows

THOMSON REUTERS
·
Oct 02

3D Investment Partners Disposes of USD 1.73 Million MediciNova Common Shares

Reuters
·
Sep 30

MediciNova Extends Office Lease, Signals Long-Term Stability

TIPRANKS
·
Sep 29

Top Premarket Decliners

MT Newswires Live
·
Sep 28

MediciNova Stock Falls on Topline Results from Phase 2 Trial for Fatty Liver Disease Treatment

Dow Jones
·
Sep 28

MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

TIPRANKS
·
Sep 28

MediciNova Posts Phase 2 MN-001 Topline Data Showing Early Triglyceride Reduction in NAFLD Patients with Type 2 Diabetes

Reuters
·
Sep 28

Medicinova - Mn-001 Generally Safe and Well Tolerated with no Drug-Related Serious Adverse Events

THOMSON REUTERS
·
Sep 28

Medicinova - Mn-001 Shows Statistically Significant Serum Triglyceride Reduction at Week 4 Versus Placebo

THOMSON REUTERS
·
Sep 28

MediciNova Inc: at End of Study, Mean Body Weight Decreased by 4.91 Lb (2.28%) in Mn-001 Group and by 0.55 Lb (0.25%) in Placebo Group

THOMSON REUTERS
·
Sep 28

Medicinova Announces Topline Results from Mn-001-Natg-202 Clinical Trial of Mn-001 (Tipelukast)

THOMSON REUTERS
·
Sep 28

Medicinova - Mn-001 Shows Statistically Significant Hdl Particle Increase at Week 24 Versus Placebo

THOMSON REUTERS
·
Sep 28

Buy Rating Reaffirmed on MediciNova as Advancing Pipeline and Upcoming Catalysts Support Unchanged $6 Price Target

TIPRANKS
·
Sep 26

MediciNova completes LPLV in Phase 2b/3 clinical trial evaluating MN-166

TIPRANKS
·
Sep 24

Medicinova - Topline Results from Double-Blind Portion Expected by End of 2026

THOMSON REUTERS
·
Sep 24

Medicinova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2B/3 Combat-ALS Trial of Mn-166 (Ibudilast)

THOMSON REUTERS
·
Sep 24

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

GlobeNewswire
·
Sep 24

NASDAQ Trade Halt Volatility Trading Pause at 09:33 Am

Reuters
·
Sep 18

Top Midday Gainers

MT Newswires Live
·
Sep 18